

COSTEM 2022 – Scientific Program

All times in CET

May 23, 2022

Thursday, October 27	
17:30-18:00	<i>Industry MTE session timeslot</i>
18:30	Welcome Reception

Friday, October 28		
	Hall A	
08:00 – 09:00	<i>Industry session timeslot</i>	
09:00 – 09:15	<i>Short Break</i>	
09:15 – 10:45	Session 1: Opening Session – CAR vs. HSCT	
09:15 – 09:25	Welcome note: Nicolaus Kröger , Germany; Arnon Nagler , Israel	
09:25 – 09:55	Does CAR T cell replace stem cell transplantation in DLBCL? Chair: Nicolaus Kröger , Germany Yes: <i>TBA</i> No: Michael Bishop , USA	
09:55 – 10:25	Controversy: Will CAR-T-cell replace stem cell transplantation in MM? Chair: Arnon Nagler , Israel Yes: Noopur Raje , USA No: Philippe Moreau , France	
10:25 – 10:45	Panel discussion: <i>All</i>	
10:45 – 11:15	<i>Coffee Break, Poster Viewing and Visit Exhibition</i>	
	Hall A	Hall B
11:15 – 12:45	Session 2: AML	Session 3: Infection complications
11:15 – 11:45	Controversy: Should MRD positivity targeted prior SCT or after SCT? Chair: Yi-Bin Chen , USA Prior: Arnon Nagler , Israel After: Michael Heuser , Germany	Controversy: Letermovir prophylaxis as secondary prophylaxis? Chair: Rafael de la Cámara , Spain Yes: Michael Boeckh , USA No: Per Ljungman , Sweden
11:45 – 12:15	Controversy: Narrow vs. broad (specific vs. nonspecific) TKI post Allo in FLT3+ AML Chair: Andreas Burchert , Germany Broad: Xiaojun Huang , China Narrow: Yi-Bin Chen , USA	Controversy: Are there evidence-based arguments for a general compulsory SarsCoV2 vaccinations? Chair: Per Ljungman , Sweden Yes: Simone Cesaro , Italy No: <i>TBA</i>
12:15 – 12:45	Panel discussion: <i>All</i>	Panel discussion: <i>All</i>
12:45 – 13:15	<i>Lunch Pick-up, Poster Viewing and Visit Exhibition</i>	

13:15 – 14:15		<i>Industry session timeslot</i>	
14:15 – 14:30		<i>Short Break</i>	
		Hall A	Hall B
14:30 – 16:00		Session 4: GVHD prophylaxis /Treatment (1)	Session 5: MDS
14:30 – 15:00		Controversy: Is there still a role for T cell depletion (CD34 purification) as GVHD prophylaxis in HLA matched (MSD and MUD) Allograft? Chair: Leonido Luznik , USA	Controversy: Are sequential conditioning regimens the standard for MDS EB1 and EB2? Chair: Bart Lee Scott , USA
14:30 – 14:45	Yes: <i>TBA</i>		Yes: Thomas Schroeder , Germany
14:45 – 15:00	No: Marcelo Pasquini , USA		No: Avichai Shimoni , Israel
15:00 – 15:30		Controversy: Can we modify schedule or dosing of PTCy? Chair: Marcelo Pasquini , USA	Controversy: Is the new Molecular IPSS helpful for decision making regarding allo? Chair: Avichai Shimoni , Israel
15:00 – 15:15	Yes: Christopher Kanakry , USA		Yes: Matteo Della Porta , Italy
15:15 – 15:30	No: Leonido Luznik , USA		No: Bart Lee Scott , USA
15:30 – 16:00		Panel discussion: <i>All</i>	Panel discussion: <i>All</i>
16:00 – 16:30 <i>Coffee Break, Poster Viewing and Visit Exhibition</i>			
16:30 – 17:30 <i>Industry session timeslot</i>			
17:30 – 17:45 <i>Short Break</i>			
		Hall A	Hall B
17:45 – 19:15		Session 6: GVHD prophylaxis/ Treatment (2)	Session 7: ALL
17:45 – 18:15		Controversy: Do novel agents replace ECP as second line treatment in cGvHD? Chair: Steven Pavletic , USA	Controversy: Is lower than 12 Gy TBI dose justified as conditioning for allo in young adult ALL? Chair: Sebastian Giebel , Poland
17:45 – 18:00	Yes: Daniel Wolff , Germany		Yes: Alexandros Spyridonidis , Greece
18:00 – 18:30	No: Hildegard Greinix , Austria		No: David Marks , UK
18:15 – 18:45		Controversy: Is CNI plus antimetabolite still the standard GvHD prophylaxis for MUD in 2022? Chair: Hildegard Greinix , Austria	Controversy: Is there still a place for upfront allo in Ph+ ALL? Chair: David Marks , UK
18:15 – 18:30	Yes: Robert Zeiser , Germany		Yes: Matthias Stelljes , Germany
18:30 – 18:45	No: <i>TBA</i>		No: Robin Foà , Italy
18:45 – 19:15		Panel discussion: <i>All</i>	Panel discussion: <i>All</i>

Saturday, October 29			
		Hall A	Hall B
08:00 – 09:30		Session 8: Acute Leukemia and CARs	Session 9: SAA
08:00 – 08:30		Controversy: Can CAR T cell therapy replace allo SCT in adult ALL? Chair: Arnon Nagler , Israel	Controversy: Can allogeneic SCT with 10/10 MUD be used as first line therapy for sAA? Chair: Carlo Dufour , Italy
08:00 – 08:15	Yes: Claire Roddie , UK		Yes: Andrea Bacigalupo , Italy
08:15 – 08:30	No: Sebastian Giebel , Poland		No: Antonio Risitano , Italy
08:30 – 09:00		Controversy: Is there a role of CAR T cell or therapy in AML in 2022?	Controversy: <i>TBA</i>

08:30 – 08:45 08:45 – 09:00	Chair: Marion Subklewe , Germany Yes: Saar Gill , USA No: Charles Craddock , UK	
09:00 – 09:30	Panel discussion: <i>All</i>	Panel discussion: <i>All</i>
09:30 – 10:00	<i>Coffee Break, Poster Viewing and Visit Exhibition</i>	
10:00 – 11:00	Industry session timeslot	
11:00 – 11:15	<i>Short Break</i>	
	Hall A	Hall B
11:15 – 12:45	Session 10: Multiple Myeloma	Session 11: Lymphoma/ Lymphatic malignancies
11:15 – 11:45 11:15 – 11:30 11:30 – 11:45	Controversy: CAR vs. Bites in R/R MM Chair: Sergio Giralt , USA CAR: <i>TBA</i> BITEs: Hermann Einsele , Germany	Controversy: NHL-patients achieving <PR 6 mo post CAR should we go Allo? Chair: David Porter , USA Yes: Peggy Lu , China No: <i>TBA</i>
11:45 – 12:15 11:45 – 12:00 12:00 – 12:15	Controversy: Is it still justified to collect CD34 cells for 2 or more transplants in MM? Chair: Hartmut Goldschmidt , Germany Yes: Pieter Sonneveld , Netherlands No: Sergio Giralt , USA	Controversy: Is there a role for cellular therapies in CAR-T .. CLL? Chair: <i>TBA</i> Yes: David Porter , USA No: Arnon Kater , Netherlands
12:15 – 12:45	Panel discussion: <i>All</i>	Panel discussion: <i>All</i>
12:45 – 13:15	<i>Lunch Pick-up, Poster Viewing and Visit Exhibition</i>	
13:15 – 14:15	Industry session timeslot	
14:15 – 14:30	<i>Short Break</i>	
	Hall A	Hall B
14:30 – 16:00	Session 12: Myelofibrosis	Session 13: Pediatric ALL
14:30 – 15:00 14:30 – 14:45 14:45 – 15:00	Controversy: Does mutation panel dictate Allo indication in myelofibrosis? Chair: Alessandro Rambaldi , Italy Yes: Francesco Passamonti , Italy No: Nicolaus Kröger , Germany	Controversy: For pediatric ALL relapsing post CD19 CAR should we go to an alternative CAR? Chair: Christina Peters , Austria Yes: Alan Wayne , USA No: Peter Bader , Germany
15:00 – 15:30 15:00 – 15:15 15:15 – 15:30	Controversy: Is there a role for haplo or cord blood transplantation in in myelofibrosis? Chair: Nicolaus Kröger , Germany Yes: Alessandro Rambaldi , Italy No: Nico Gagelmann , Germany	Controversy: Can PBSC be used as stem cell source in MUD pediatric ALL? Chair: Alan Wayne , USA Yes: Christina Peters , Austria No: Michael Pulsipher , USA
15:30 – 16:00	Panel discussion: <i>All</i>	Panel discussion: <i>All</i>
16:00 – 16:30	<i>Coffee Break, Poster Viewing and Visit Exhibition</i>	
16:30 – 17:30	Industry session timeslot	
17:30 – 17:45	<i>Short Break</i>	
	Hall A	Hall B

17:45 – 19:15	Session 14: Stem cell donors	Session 15: Hemoglobinopathy
17:45 – 18:15	Controversy: Can expanded CBT compete with Haplo SCT? Chair: Vanderson Rocha , Brazil	Controversy: Is PTCY the preferred GvHD prophylaxis after haplo-ident SCT in sickle cell anemia? Chair: Rupert Handgretinger , Germany
18:15 – 18:30	Yes: Guillermo Sanz , Spain	Yes: Josu de la Fuente , UK
18:30 – 18:45	No: Francesca Bonifazi , Italy	No: Selim Corbacioglu , Germany
18:45 – 19:15	Controversy: Is PBSC as stem cell source equal to BM after Haplo PTCy? Chair: Francesca Bonifazi , Italy	Controversy: Can gene therapy replace allogeneic SCT in thalassemia? Chair: Selim Corbacioglu , Germany
18:45 – 19:00	Yes: Vanderson Rocha , Brazil	Yes: Rupert Handgretinger , Germany
19:00 – 19:15	No: TBA	No: Suradej Hongeng , Thailand
19:15 – 19:45	Panel discussion: <i>All</i>	Panel discussion: <i>All</i>
19:45 – 20:30	<i>COSTEM Poster Walk and Awards</i>	

Sunday, October 30	
	Hall A
09:00 – 10:30	Session 16: Cellular therapies
09:00 – 09:30	Controversy: Can allo NK CAR complete with auto CAR T? Chair: TBA
09:00 – 09:15	Yes: Evelyn Ullrich , Germany
09:15 – 09:30	No: TBA
09:30 – 10:00	Controversy: TBA
09:30 – 09:45	
09:45 – 10:00	
10:00 – 10:30	Panel discussion: <i>All</i>
10:30 – 11:00	<i>Coffee Break</i>
11:00 – 12:30	Session 17: Selection of CAR T cells
11:00 – 11:30	Controversy: Should we preference a CD19 CAR construct in RR DLBCL? Chair: Michael Bishop , USA
11:00 – 11:15	Yes: Wolfgang Bethge , Germany
11:15 – 11:30	No: Marion Subklewe , Germany
11:30 – 12:00	Controversy: Should we preference a BMCA CAR construct in R/R myeloma? Chair: Hermann Einsele , Germany
11:30 – 11:45	Yes: Michael Hudecek , Germany
11:45 – 12:00	No: He Huang , China
12:00 – 12:30	Panel discussion: <i>All</i>
12:30	Closing remarks: Nicolaus Kröger , Germany; Arnon Nagler , Israel